ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Activation of the nucleus nuclear factor erythroid 2-related factor 2ghrelin/growth hormone secretagogue receptor 1a signaling by Yueju pill confers cardioprotective and antidepressant effects.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo investigate the efficacy and mechanistic foundations of the Traditional Chinese Medicine Yueju pill (YJP, ) for treating the complex comorbidity of heart failure and depression.
methodsC57BL/6 male mice were used to establish a robust congestive heart failure (CHF) model with concomitant depressive manifestations. Echocardiographic assessments were conducted to evaluate cardiac structure and function in the mice. Depression-related behavioral tests and the detection of monoamine neurotransmitters were performed to assess the antidepressant-like effectiveness of YJP. Western blot analysis was conducted to measure the expression levels of key components in the nuclear factor erythroid 2-related factor 2 (NRF2)/heme oxygenase 1 (HO1) antioxidant pathway, NRF2/brain-derived neurotrophic factor (BDNF) pathway, and ghrelin/growth hormone secretagogue receptor (GHS-R)1a pathway in the myocardium and hippocampus. To explore the mechanistic role of the ghrelin/GHS-R1a pathway, the ghrelin receptor antagonist D-Lys3-growth hormone-releasing peptide-6 was introduced to enable the iterative evaluation of the aforementioned parameters.
resultsYJP improved cardiac dysfunction and myocardial fibrosis and markedly ameliorated depressive behaviors. It also improved neuron damage, boosted the growth of dendritic spines to enhance synaptic plasticity, and alleviated monoamine neurotransmitter imbalances. Additionally, the NRF2/BDNF, ghrelin/GHS-R1a, and NRF2/HO1 antioxidant pathways were promoted by YJP, with the increased expression of key components of the three pathways. The addition of a GHS-R1a antagonist impaired the antidepressant and cardioprotective effects of YJP.
conclusionsYJP effectively improved cardiac dysfunction and depressive-like behaviors in mice by activating NRF2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.